Back to discover
Disease

Skin squamous cell carcinoma

Active therapeutic pipeline
Also known as cutaneous squamous cell carcinoma, epidermoid carcinoma of skin, epidermoid carcinoma of the skin, epidermoid skin carcinoma+7 more

cutaneous squamous cell carcinoma, epidermoid carcinoma of skin, epidermoid carcinoma of the skin, epidermoid skin carcinoma, skin squamous cell cancer, squamous cell carcinoma - skin, squamous cell carcinoma of skin, squamous cell carcinoma of the skin, squamous cell skin carcinoma, zone of skin squamous cell carcinoma, CSCC.

14
Clinical trials
12
Associated genes
4
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Libtayo (EMA)

Regulatory2019-06-28EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones5View
Results posted 2
Results expected 3
Activity timeline5

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Cemiplimabapproved

Approval — Cutaneous Squamous Cell Carcinoma Libtayo as monotherapy is indicated for the treatment… (2019)

Clinical trials

9 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
14
All trials
6
Active
0
Late-stage
5
Completed
Recently completed

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase 1 · Completed · M.D. Anderson Cancer Center

A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors

Phase 2 · Completed · M.D. Anderson Cancer Center

A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma

Phase 2 · Completed · Emory University

Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Phase 2 · Completed · M.D. Anderson Cancer Center

A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Phase 2 · Completed · Traws Pharma, Inc.

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApproval — Cemiplimab· Cutaneous Squamous Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. Libtayo as monotherapy is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation (see section 5.1 for selection criteria).  Basal Cell Carcinoma Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Non-Small Cell Lung Cancer Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ? 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. Libtayo in combination with platinum?based chemotherapy is indicated for the first?line treatment of adult patients with NSCLC expressing PD-L1 (in ? 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. Cervical Cancer Libtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

FAT10.46ARID20.42NOTCH20.42AXIN20.38ATR0.37JUN0.37TENT5C0.37MDM20.37PER10.37BCL60.37ATP2B30.37BCL90.37

Disease biology

4 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Serine/threonine-protein kinase ATRvia ATR0.37B-cell lymphoma 6 proteinvia BCL60.37Baculoviral IAP repeat-containing protein 3via BIRC30.37Wee1-like protein kinasevia WEE10.37

Reference

Authoritative identity, definition & identifiers.

Synonyms

cutaneous squamous cell carcinoma, epidermoid carcinoma of skin, epidermoid carcinoma of the skin, epidermoid skin carcinoma, skin squamous cell cancer, squamous cell carcinoma - skin, squamous cell carcinoma of skin, squamous cell carcinoma of the skin, squamous cell skin carcinoma, zone of skin squamous cell carcinoma, CSCC

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.